GlassScriptPhysician profile
Mario R Capio
NPI 1356383863
$6,477.32
in general payments reported to CMS, 2019-2025
37 companies · $871 in 2025
The $871 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $781 · 2021: $884 · 2022: $892 · 2023: $738 · 2024: $1,298 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,907.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,502.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,213.95 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Merck Sharp & Dohme LLC | $666.45 | 2019-2023 | Belsomra, Steglatro |
| Exact Sciences Corporation | $419.50 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $329.99 | 2020-2025 | |
| Bausch Health US, LLC | $246.72 | 2021-2024 | Aplenzin |
| Abbott Laboratories | $201.16 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Esperion Therapeutics, INC. | $186.71 | 2020-2021 | |
| Allergan, INC. | $184.03 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $169.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $148.95 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $138.84 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $96.75 | 2019-2021 | |
| Astellas Pharma US INC | $87.65 | 2024-2025 | Veozah |
| Arbor Pharmaceuticals, INC. | $83.81 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $66.77 | 2025 | Omnipod |
| Althera Pharmaceuticals LLC | $65.93 | 2021-2022 | |
| Ge Healthcare | $64.17 | 2021-2023 | |
| Eisai INC. | $58.04 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $54.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.97 | 2022-2025 | Jardiance |
| Sanofi Pasteur INC. | $47.07 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $44.86 | 2019-2024 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $40.23 | 2019 | |
| Dexcom, INC. | $31.14 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $30.22 | 2023 | Quviviq |
| Amgen INC. | $29.55 | 2019-2024 | Repatha |
| Azurity Pharmaceuticals, INC. | $27.85 | 2023 | Horizant |
| Novartis Pharmaceuticals Corporation | $27.66 | 2021-2024 | |
| Daiichi Sankyo INC. | $27.29 | 2019-2021 | |
| Dermira, INC. | $27.00 | 2020 | |
| Medtronic, INC. | $26.32 | 2022 | |
| Vistapharm, INC. | $25.14 | 2021 | |
| Boston Scientific Corporation | $16.13 | 2019 | |
| Medtronic USA, INC. | $14.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.55 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Capio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.